Alnylam books $38M in Onpattro sales in Q2

Alnylam Pharmaceuticals (NASDAQ:ALNY) Q2 results: Revenues: $44.7M (+49%). Onpattro sales: $38.2M.

Net loss: ($219.5M); loss/share: ($2.02).

Data readouts from pivotal studies of inclisiran and lumasiran expected in H2. Phase 3s to be initiated: APOLLO-B (patisiran) in ATTR amyloidosis with cardiomyopathy, HELIOS-B (vutrisiran) in ATTR amyloidosis with cardiomyopathy and ILLUMINATE-C (lumasiran) in PH1 with severe renal impairment.

Shares are down 5% premarket on light volume.

Previously: Alnylam Pharmaceuticals EPS beats by $0.33, beats on revenue(Aug. 6)

https://seekingalpha.com/news/3487466-alnylam-books-38m-onpattro-sales-q2